; (2) nonalcoholic steatohepatitis; (3) obesity; (4) diabetes and other metabolic disorders; and (5) any other conditions determined appropriate by the Secretary. (b) Membership The task force established under subsection (a) shall be composed of not more than 12 members to be appointed by the Secretary and shall include representatives of each of the following groups: (1) Physician specialists, including in hepatology, gastroenterology, endocrinology, cardiology, and endocrinology. (2) Experts in public health and epidemiology. (3) Patient advocates. (4) Non-voting representatives of Federal agencies, including the Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, and the Office of the Assistant Secretary for Health of the Department of Health and Human Services. (5) Non-voting representatives of manufacturers of drugs, devices, or diagnostic tools approved by the Food and Drug Administration for the treatment of any of the conditions specified in subsection (a). (c) Development of recommendations In developing the recommendations under subsection (a), the task force established under such subsection shall consider— (1) guidelines issued by the American Association for the Study of Liver Diseases, published evidence, recommendations of the United States Preventive Services Task Force, and other information it determines appropriate in developing such recommendations